Collegium Reports Record Full-Year 2020 Revenue of $310.0 Million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Collegium Pharma (COLL) Misses Q4 EPS by 9c
February 25, 2021 5:18 PM ESTCollegium Pharma (NASDAQ: COLL) reported Q4 EPS of $0.20, $0.09 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $76.3 million versus the consensus estimate of $77.41 million.
Our differentiated pain portfolio performed well during the fourth quarter, laying the groundwork for a strong start in the new year, said... More
